THANK YOU FOR SUBSCRIBING
By organizing health information and applying AI technology, OM1 helps customers generate and use real-world evidence more rapidly and effectively to gain regulatory approval.
FREMONT, CA: OM1, a health technology company focused on real-world outcomes for chronic conditions, announced an $85 million financing led by D1 Capital Partners, Kaiser Permanente, and Breyer Capital, with participation from existing investors, including General Catalyst (GC), Polaris Partners, Scale Venture Partners, 7wire Ventures, and Glikvest.
OM1 partners with providers, medical societies, payers, and manufacturers to harness real-world data for advancing medical research, evaluating health outcomes, obtaining regulatory approvals, and personalizing treatment in chronic disease areas, such as dermatology, rheumatology, cardiology, gastroenterology, respiratory, neurosciences, and behavioral health. In addition to these efforts, OM1 develops state-of-the-art artificial intelligence (AI) models and solutions for finding patients and predicting outcomes.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
"There has been limited focus on using real-world data for autoimmune and other chronic conditions – despite those conditions representing more than $1.6 trillion in healthcare costs in the U.S alone," said Dr. Richard Gliklich, CEO and founder of OM1. "With this funding, OM1 will expand our work building robust real-world data networks that are changing the research paradigm and enabling more precise treatments."
Increasingly healthcare stakeholders, including regulators, payers, and providers, are seeking real-world evidence for supporting outcomes-based decision making. By organizing health information and applying AI technology, OM1 helps customers generate and use real-world evidence more rapidly and effectively to gain regulatory approval, to understand the effectiveness, safety, and value of treatments, and to personalize care.
Daniel Sundheim, the founder of D1 Capital Partners, noted, "We believe OM1 is at the forefront of innovation in applying real-world data and AI in impactful ways. We are excited to support their mission as they continue to expand their products in pursuit of improving patient outcomes."
More in News